

Celso Arango

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8799953/publications.pdf>

Version: 2024-02-01

511
papers

26,482
citations

7551

77
h-index

11899

134
g-index

593
all docs

593
docs citations

593
times ranked

25153
citing authors

#	ARTICLE	IF	CITATIONS
1	Common variants conferring risk of schizophrenia. <i>Nature</i> , 2009, 460, 744-747.	13.7	1,572
2	How mental health care should change as a consequence of the COVID-19 pandemic. <i>Lancet Psychiatry</i> , 2020, 7, 813-824.	3.7	1,101
3	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	13.7	929
4	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. <i>Lancet Psychiatry</i> , 2019, 6, 427-436.	3.7	528
5	Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. <i>Molecular Psychiatry</i> , 2018, 23, 1261-1269.	4.1	522
6	Nitrous oxide emission from denitrification in stream and river networks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 214-219.	3.3	517
7	Impact of coronavirus syndromes on physical and mental health of health care workers: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 275, 48-57.	2.0	438
8	Preventive strategies for mental health. <i>Lancet Psychiatry</i> , 2018, 5, 591-604.	3.7	390
9	The impact of COVID-19 lockdown on child and adolescent mental health: systematic review. <i>European Child and Adolescent Psychiatry</i> , 2023, 32, 1151-1177.	2.8	364
10	Cortical and Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group. <i>American Journal of Psychiatry</i> , 2018, 175, 359-369.	4.0	356
11	Negative symptoms of schizophrenia: new developments and unanswered research questions. <i>Lancet Psychiatry</i> , 2018, 5, 664-677.	3.7	316
12	Prevention of Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 755.	6.0	287
13	Efficacy of Functional Remediation in Bipolar Disorder: A Multicenter Randomized Controlled Study. <i>American Journal of Psychiatry</i> , 2013, 170, 852-859.	4.0	269
14	The Continuum of Psychotic Symptoms in the General Population: A Cross-national Study. <i>Schizophrenia Bulletin</i> , 2012, 38, 475-485.	2.3	266
15	Significance and Meaning of Neurological Signs in Schizophrenia: Two Decades Later. <i>Schizophrenia Bulletin</i> , 2005, 31, 962-977.	2.3	240
16	Standardized remission criteria in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 91-95.	2.2	238
17	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <i>JAMA Psychiatry</i> , 2018, 75, 36.	6.0	235
18	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	2.3	229

#	ARTICLE	IF	CITATIONS
19	Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. <i>Nature Neuroscience</i> , 2017, 20, 1217-1224.	7.1	212
20	Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 280-286.	1.1	210
21	Quality of life and disability in patients with obsessive-compulsive disorder. <i>European Psychiatry</i> , 2001, 16, 239-245.	0.1	201
22	Common variants at VRK2 and TCF4 conferring risk of schizophrenia. <i>Human Molecular Genetics</i> , 2011, 20, 4076-4081.	1.4	193
23	Violence in Inpatients With Schizophrenia: A Prospective Study. <i>Schizophrenia Bulletin</i> , 1999, 25, 493-503.	2.3	192
24	Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics. <i>JAMA Psychiatry</i> , 2016, 73, 247.	6.0	189
25	Psychosocial risk factors for suicidality in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2020, 29, 759-776.	2.8	187
26	Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. <i>European Neuropsychopharmacology</i> , 2009, 19, 629-635.	0.3	184
27	Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , 2021, 20, 200-221.	4.8	183
28	Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. <i>European Child and Adolescent Psychiatry</i> , 2020, 29, 1195-1205.	2.8	181
29	The stress and psychological morbidity of the Alzheimer patient caregiver. , 1999, 14, 701-710.		179
30	Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. <i>Schizophrenia Research</i> , 2007, 90, 162-173.	1.1	177
31	Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2019, 45, 742-751.	2.3	172
32	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , 2011, 21, 621-645.	0.3	168
33	Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets. <i>Nature Communications</i> , 2019, 10, 4958.	5.8	167
34	Predictors of outcome in early-onset psychosis: a systematic review. <i>NPJ Schizophrenia</i> , 2015, 1, 14005.	2.0	161
35	Mental health research priorities for Europe. <i>Lancet Psychiatry</i> , 2015, 2, 1036-1042.	3.7	158
36	Inflammation in schizophrenia: A question of balance. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 612-626.	2.9	155

#	ARTICLE	IF	CITATIONS
37	Schizophrenia--Time to Commit to Policy Change. Schizophrenia Bulletin, 2014, 40, S165-S194.	2.3	153
38	Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophrenia Research, 2010, 119, 101-109.	1.1	151
39	White matter microstructure correlates of mathematical giftedness and intelligence quotient. Human Brain Mapping, 2014, 35, 2619-2631.	1.9	144
40	Psychiatry in the aftermath of COVID-19. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 105-110.	1.0	142
41	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry, 2018, 5, 797-807.	3.7	141
42	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	6.0	136
43	Progressive Brain Changes in Children and Adolescents With First-Episode Psychosis. Archives of General Psychiatry, 2012, 69, 16.	13.8	135
44	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. NeuroImage, 2020, 218, 116956.	2.1	135
45	The identification, assessment and management of difficult-to-treat depression: An international consensus statement. Journal of Affective Disorders, 2020, 267, 264-282.	2.0	133
46	ECNP consensus meeting. Bipolar depression. Nice, March 2007. European Neuropsychopharmacology, 2008, 18, 535-549.	0.3	131
47	Treatment of negative symptoms: Where do we stand, and where do we go?. Schizophrenia Research, 2017, 186, 55-62.	1.1	131
48	What is good mental health? A scoping review. European Neuropsychopharmacology, 2020, 31, 33-46.	0.3	131
49	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry, 2019, 18, 173-182.	4.8	127
50	Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. World Psychiatry, 2021, 20, 417-436.	4.8	127
51	Advantages and disadvantages of combination treatment with antipsychotics. European Neuropsychopharmacology, 2009, 19, 520-532.	0.3	125
52	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. American Journal of Psychiatry, 2020, 177, 834-843.	4.0	120
53	Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers. American Journal of Psychiatry, 2006, 163, 488-493.	4.0	117
54	Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use. Schizophrenia Bulletin, 2011, 37, 631-639.	2.3	112

#	ARTICLE	IF	CITATIONS
55	Early interventions in risk groups for schizophrenia: what are we waiting for?. <i>NPJ Schizophrenia</i> , 2016, 2, 16003.	2.0	111
56	ROAMER: roadmap for mental health research in Europe. <i>International Journal of Methods in Psychiatric Research</i> , 2014, 23, 1-14.	1.1	109
57	The Human Cerebral Cortex Flattens during Adolescence. <i>Journal of Neuroscience</i> , 2013, 33, 15004-15010.	1.7	108
58	Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 88-97.	2.2	106
59	Prediction of Neuropsychological Performance by Neurological Signs in Schizophrenia. <i>American Journal of Psychiatry</i> , 1999, 156, 1349-1357.	4.0	102
60	Neurological Signs and the Heterogeneity of Schizophrenia. <i>American Journal of Psychiatry</i> , 2000, 157, 560-565.	4.0	100
61	Trait and State Attributes of Insight in First Episodes of Early-Onset Schizophrenia and Other Psychoses: A 2-Year Longitudinal Study. <i>Schizophrenia Bulletin</i> , 2011, 37, 38-51.	2.3	100
62	Differential Neurodevelopmental Trajectories in Patients With Early-Onset Bipolar and Schizophrenia Disorders. <i>Schizophrenia Bulletin</i> , 2014, 40, S138-S146.	2.3	100
63	De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. <i>Nature Neuroscience</i> , 2020, 23, 179-184.	7.1	100
64	Criterios de valoración clínicos y de funcionamiento en un estudio de interacción gen-ambiente en primeros episodios psicóticos (PEPs). <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 4-16.	1.0	99
65	Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. <i>British Journal of Psychiatry</i> , 2016, 208, 87-93.	1.7	95
66	Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 435-444.	1.0	95
67	Annual Research Review: Prevention of psychosis in adolescents – systematic review and meta-analysis of advances in detection, prognosis and intervention. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021, 62, 657-673.	3.1	95
68	Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. <i>BMC Psychiatry</i> , 2011, 11, 26.	1.1	94
69	Magnetic Resonance Imaging and the Prediction of Outcome in First-Episode Schizophrenia: A Review of Current Evidence and Directions for Future Research. <i>Schizophrenia Bulletin</i> , 2015, 41, 574-583.	2.3	94
70	The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. <i>Schizophrenia Bulletin</i> , 2015, 41, 559-573.	2.3	93
71	Bitopertin in Negative Symptoms of Schizophrenia – Results From the Phase III FlashLyte and DayLyte Studies. <i>Biological Psychiatry</i> , 2017, 82, 8-16.	0.7	92
72	Morphometric Assessment of the Heteromodal Association Cortex in Schizophrenia. <i>American Journal of Psychiatry</i> , 2004, 161, 322-331.	4.0	92

#	ARTICLE	IF	CITATIONS
73	Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. <i>Nature Medicine</i> , 2020, 26, 1912-1918.	15.2	90
74	Lessons Learned From the Coronavirus Health Crisis in Madrid, Spain: How COVID-19 Has Changed Our Lives in the Last 2 Weeks. <i>Biological Psychiatry</i> , 2020, 88, e33-e34.	0.7	90
75	Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. <i>World Psychiatry</i> , 2013, 12, 251-257.	4.8	89
76	Metabolic and Hormonal Side Effects in Children and Adolescents Treated With Second-Generation Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1166-1175.	1.1	89
77	Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 121-135.	1.0	87
78	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. <i>Molecular Psychiatry</i> , 2021, 26, 4496-4510.	4.1	87
79	Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study). <i>Schizophrenia Research</i> , 2009, 113, 129-137.	1.1	86
80	The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. <i>Schizophrenia Research</i> , 2007, 91, 226-237.	1.1	85
81	Common variant at 16p11.2 conferring risk of psychosis. <i>Molecular Psychiatry</i> , 2014, 19, 108-114.	4.1	85
82	The Relationship of Clozapine and Haloperidol Treatment Response to Prefrontal, Hippocampal, and Caudate Brain Volumes. <i>American Journal of Psychiatry</i> , 2003, 160, 1421-1427.	4.0	84
83	Developmental Differences Between Schizophrenia and Bipolar Disorder. <i>Schizophrenia Bulletin</i> , 2017, 43, 1176-1189.	2.3	81
84	Pharmacological approaches to treating negative symptoms: A review of clinical trials. <i>Schizophrenia Research</i> , 2013, 150, 346-352.	1.1	80
85	The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. <i>European Psychiatry</i> , 2004, 19, 21-26.	0.1	77
86	Regional Gray Matter Volume Deficits in Adolescents With First-Episode Psychosis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2008, 47, 1311-1320.	0.3	77
87	Longitudinal Brain Changes in Early-Onset Psychosis. <i>Schizophrenia Bulletin</i> , 2007, 34, 341-353.	2.3	76
88	Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 1179-1190.e4.	0.3	76
89	Genetic variants associated with longitudinal changes in brain structure across the lifespan. <i>Nature Neuroscience</i> , 2022, 25, 421-432.	7.1	75
90	A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. <i>Schizophrenia Research</i> , 2008, 104, 1-12.	1.1	74

#	ARTICLE	IF	CITATIONS
91	Depression in bipolar disorder versus major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. <i>Bipolar Disorders</i> , 2012, 14, 271-282.	1.1	74
92	The neurobiology of autism spectrum disorders. <i>European Psychiatry</i> , 2014, 29, 11-19.	0.1	72
93	Deficit psychopathology and a paradigm shift in schizophrenia research. <i>Biological Psychiatry</i> , 1999, 46, 352-360.	0.7	71
94	Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. <i>European Psychiatry</i> , 2006, 21, 34-40.	0.1	70
95	Neuropsychological functioning in early-onset first-episode psychosis: comparison of diagnostic subgroups. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 225-233.	1.8	69
96	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2019, 49, 1378-1391.	2.7	69
97	Assessment of School Anti-Bullying Interventions. <i>JAMA Pediatrics</i> , 2021, 175, 44.	3.3	69
98	Functional Impairment in Patients with Remitted Bipolar Disorder. <i>Psychotherapy and Psychosomatics</i> , 2008, 77, 390-392.	4.0	68
99	Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 1-8.	1.0	68
100	The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics. <i>World Psychiatry</i> , 2022, 21, 168-188.	4.8	67
101	Psychopathological sequelae of the 11 March terrorist attacks in Madrid. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 258, 28-34.	1.8	66
102	Olanzapine compared to quetiapine in adolescents with a first psychotic episode. <i>European Child and Adolescent Psychiatry</i> , 2009, 18, 418-428.	2.8	66
103	Mathematically gifted adolescents use more extensive and more bilateral areas of the fronto-parietal network than controls during executive functioning and fluid reasoning tasks. <i>NeuroImage</i> , 2011, 57, 281-292.	2.1	65
104	Cortical morphology of adolescents with bipolar disorder and with schizophrenia. <i>Schizophrenia Research</i> , 2014, 158, 91-99.	1.1	65
105	A quantitative approach to neuropsychiatry: The why and the how. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 3-9.	2.9	63
106	Antipsychotic-Related Abnormal Involuntary Movements and Metabolic and Endocrine Side Effects in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 487-501.	0.7	62
107	Individual differences in the dominance of interhemispheric connections predict cognitive ability beyond sex and brain size. <i>NeuroImage</i> , 2017, 155, 234-244.	2.1	62
108	Cognitive reserve as a predictor of two year neuropsychological performance in early onset first-episode schizophrenia. <i>Schizophrenia Research</i> , 2013, 143, 125-131.	1.1	61

#	ARTICLE	IF	CITATIONS
109	Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The ENIGMA adventure. <i>Human Brain Mapping</i> , 2022, 43, 37-55.	1.9	61
110	Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 145-154.	2.2	60
111	Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: A 2-year longitudinal study. <i>Schizophrenia Research</i> , 2014, 152, 130-138.	1.1	59
112	Predictors of Suicide Attempt in Early-Onset, First-Episode Psychoses. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 59-66.	1.1	59
113	Antipsychotic Treatment in Child and Adolescent First-Episode Psychosis: A Longitudinal Naturalistic Approach. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 327-336.	0.7	58
114	Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 344-357.	2.3	58
115	Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 1536-1548.	2.7	58
116	Detecting schizophrenia at the level of the individual: relative diagnostic value of whole-brain images, connectome-wide functional connectivity and graph-based metrics. <i>Psychological Medicine</i> , 2020, 50, 1852-1861.	2.7	57
117	Neuropsychological evidence for abnormal neurodevelopment associated with early-onset psychoses. <i>Psychological Medicine</i> , 2013, 43, 757-768.	2.7	56
118	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <i>European Neuropsychopharmacology</i> , 2015, 25, 1513-1531.	0.3	56
119	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. <i>Schizophrenia Bulletin</i> , 2020, 46, 432-441.	2.3	56
120	Integrating machine learning and multimodal neuroimaging to detect schizophrenia at the level of the individual. <i>Human Brain Mapping</i> , 2020, 41, 1119-1135.	1.9	56
121	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2020, 41, 28-39.	0.3	56
122	The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. <i>European Journal of Clinical Nutrition</i> , 2014, 68, 146-152.	1.3	55
123	Does Diagnostic Classification of Early-Onset Psychosis Change Over Follow-Up?. <i>Child Psychiatry and Human Development</i> , 2008, 39, 137-145.	1.1	54
124	Plasma antioxidant capacity is reduced in Asperger syndrome. <i>Journal of Psychiatric Research</i> , 2012, 46, 394-401.	1.5	54
125	Progressive brain changes in children and adolescents with early-onset psychosis: A meta-analysis of longitudinal MRI studies. <i>Schizophrenia Research</i> , 2016, 173, 132-139.	1.1	54
126	DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 873-879.	1.1	53

#	ARTICLE	IF	CITATIONS
127	Cortical structural abnormalities in deficit versus nondeficit schizophrenia. <i>Schizophrenia Research</i> , 2012, 136, 51-54.	1.1	52
128	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. <i>Translational Psychiatry</i> , 2019, 9, 20.	2.4	52
129	Two-year diagnostic stability in early-onset first-episode psychosis. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2011, 52, 1089-1098.	3.1	51
130	Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2182-2191.	0.7	51
131	Brain morphology and neurological soft signs in adolescents with first-episode psychosis. <i>British Journal of Psychiatry</i> , 2009, 195, 227-233.	1.7	50
132	Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. <i>Schizophrenia Research</i> , 2012, 137, 58-65.	1.1	50
133	Altered white matter microstructure in 22q11.2 deletion syndrome: a multisite diffusion tensor imaging study. <i>Molecular Psychiatry</i> , 2020, 25, 2818-2831.	4.1	50
134	Is attempted suicide different in adolescent and adults?. <i>Psychiatry Research</i> , 2008, 157, 131-137.	1.7	49
135	Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. <i>Bipolar Disorders</i> , 2010, 12, 172-184.	1.1	49
136	The Relationship Between White Matter Microstructure and General Cognitive Ability in Patients With Schizophrenia and Healthy Participants in the ENIGMA Consortium. <i>American Journal of Psychiatry</i> , 2020, 177, 537-547.	4.0	49
137	Progression of Brain Volume Changes in Adolescent-Onset Psychosis. <i>Schizophrenia Bulletin</i> , 2009, 35, 233-243.	2.3	48
138	Assessment of the increase in variability when combining volumetric data from different scanners. <i>Human Brain Mapping</i> , 2009, 30, 355-368.	1.9	48
139	Association study between obsessive-compulsive disorder and serotonergic candidate genes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 765-770.	2.5	47
140	Violence among schizophrenia outpatients compliant with medication: prevalence and associated factors. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 218-225.	2.2	47
141	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Schizophrenia Bulletin</i> , 2015, 41, 549-558.	2.3	47
142	Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 158-173.	1.0	47
143	Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure. <i>Schizophrenia Bulletin</i> , 2019, 45, 69-79.	2.3	47
144	The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110326.	2.5	47

#	ARTICLE	IF	CITATIONS
145	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 328-333.	1.1	46
146	Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. <i>Frontiers in Neuroendocrinology</i> , 2017, 45, 25-34.	2.5	46
147	Randomized trial of omega-3 for autism spectrum disorders: Effect on cell membrane composition and behavior. <i>European Neuropsychopharmacology</i> , 2017, 27, 1319-1330.	0.3	46
148	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 960-965.	2.3	46
149	Gyral and Sulcal Cortical Thinning in Adolescents with First Episode Early-Onset Psychosis. <i>Biological Psychiatry</i> , 2009, 66, 1047-1054.	0.7	45
150	Autism Spectrum Disorder: Does Neuroimaging Support the DSM-5 Proposal for a Symptom Dyad? A Systematic Review of Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Studies. <i>Journal of Autism and Developmental Disorders</i> , 2012, 42, 1326-1341.	1.7	44
151	Early intervention in psychosis: From clinical intervention to health system implementation. <i>Microbial Biotechnology</i> , 2018, 12, 757-764.	0.9	44
152	Olanzapine Effects on Auditory Sensory Gating in Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 2066-2068.	4.0	43
153	Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study. <i>Psychological Medicine</i> , 2009, 39, 1433-1445.	2.7	43
154	Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. <i>Psychological Medicine</i> , 2016, 46, 291-301.	2.7	43
155	The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 35-46.	2.8	43
156	Modelling gene-environment interaction in first episodes of psychosis. <i>Schizophrenia Research</i> , 2017, 189, 181-189.	1.1	43
157	Evidence for the early clinical relevance of hallucinatoryâ€delusional states in the general population. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 482-493.	2.2	42
158	Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study. <i>Schizophrenia Research</i> , 2014, 156, 23-29.	1.1	42
159	BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents. <i>Journal of Psychopharmacology</i> , 2016, 30, 416-421.	2.0	41
160	The European Network of National Schizophrenia Networks Studying Geneâ€Environment Interactions (EU-GEI): Incidence and First-Episode Caseâ€Control Programme. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 645-657.	1.6	41
161	Neuropsychological functioning in adolescents with first episode psychosis: A two-year follow-up study. <i>European Psychiatry</i> , 2008, 23, 375-383.	0.1	40
162	Can positive family factors be protective against the development of psychosis?. <i>Psychiatry Research</i> , 2011, 186, 28-33.	1.7	40

#	ARTICLE	IF	CITATIONS
163	Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis. <i>Pediatrics</i> , 2019, 144, .	1.0	40
164	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. <i>Molecular Autism</i> , 2020, 11, 66.	2.6	40
165	At Issue: Stress, Hippocampal Neuronal Turnover, and Neuropsychiatric Disorders. <i>Schizophrenia Bulletin</i> , 2001, 27, 477-480.	2.3	39
166	Antidepressants in child and adolescent depression: where are the bugs?. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 184-195.	2.2	39
167	Lessons Learned About Poor Insight. <i>Schizophrenia Bulletin</i> , 2011, 37, 27-28.	2.3	39
168	Longitudinal study of neurological soft signs in first-episode early-onset psychosis. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2012, 53, 323-331.	3.1	39
169	Psychopathology in Children and Adolescents with ASD Without Mental Retardation. <i>Journal of Autism and Developmental Disorders</i> , 2013, 43, 2442-2449.	1.7	39
170	The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1233-e1241.	1.1	39
171	Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 741-745.	2.5	38
172	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). <i>European Neuropsychopharmacology</i> , 2019, 29, 1301-1311.	0.3	38
173	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 1329-1337.	2.7	38
174	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	1.4	38
175	Structural Neuroimaging in Adolescents With a First Psychotic Episode. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 1151-1157.	0.3	37
176	Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 26-31.	2.5	37
177	Increased Risk of Diabetes Mellitus Among Persons With Psychotic Symptoms. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1592-1599.	1.1	37
178	Reduced Gyrfication Is Related to Reduced Interhemispheric Connectivity in Autism Spectrum Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 668-676.	0.3	37
179	Predictors of schizophrenia spectrum disorders in early-onset first episodes of psychosis: a support vector machine model. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 427-440.	2.8	37
180	Quando la asistencia no sigue a la evidencia: el caso de la falta de programas de intervenci3n temprana en psicosis en EspaAa. <i>Revista De PsiquiatrAa Y Salud Mental</i> , 2017, 10, 78-86.	1.0	37

#	ARTICLE	IF	CITATIONS
181	Cognitive Functioning in Children and Adolescents in Their First Episode of Psychosis. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 159-162.	0.5	36
182	Neuropsychological correlates of P50 sensory gating in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 143, 102-106.	1.1	36
183	Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain. <i>Schizophrenia Research</i> , 2014, 159, 107-113.	1.1	36
184	Modeling Determinants of Medication Attitudes and Poor Adherence in Early Nonaffective Psychosis: Implications for Intervention. <i>Schizophrenia Bulletin</i> , 2015, 41, 584-596.	2.3	36
185	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e182.	1.8	36
186	Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. <i>Molecular Autism</i> , 2022, 13, 10.	2.6	36
187	The effect of quetiapine on aggression and hostility in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2005, 20, 237-241.	0.7	35
188	Differential role of serotonergic polymorphisms in alcohol and heroin dependence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 695-700.	2.5	35
189	Una década del proyecto de primeros episodios psicóticos (PEPs): avanzando hacia una psiquiatría de precisión. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 135-140.	1.0	35
190	Fluoxetine as an Adjunct to Conventional Antipsychotic Treatment of Schizophrenia Patients with Residual Symptoms. <i>Journal of Nervous and Mental Disease</i> , 2000, 188, 50-53.	0.5	35
191	Relationship of Awareness of Dyskinesia in Schizophrenia to Insight Into Mental Illness. <i>American Journal of Psychiatry</i> , 1999, 156, 1097-1099.	4.0	35
192	Intervention for Adolescents With Early-Onset Psychosis and Their Families: A Randomized Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 688-696.	0.3	34
193	Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 623-633.	2.7	34
194	Managing acute exacerbations of schizophrenia: focus on quetiapine. <i>Current Medical Research and Opinion</i> , 2004, 20, 619-626.	0.9	33
195	P50 gating in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , 2010, 119, 183-190.	1.1	33
196	Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study. <i>European Neuropsychopharmacology</i> , 2011, 21, 867-875.	0.3	33
197	Premorbid impairments in early-onset psychosis: Differences between patients with schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2013, 146, 103-110.	1.1	33
198	Antipsychotic Use in Children and Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 613-619.	0.7	33

#	ARTICLE	IF	CITATIONS
199	A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis. <i>Schizophrenia Research</i> , 2014, 158, 126-133.	1.1	33
200	Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2172-2181.	0.7	33
201	Sensory-to-Cognitive Systems Integration Is Associated With Clinical Severity in Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2020, 59, 422-433.	0.3	33
202	The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. <i>Annals of General Psychiatry</i> , 2020, 19, 42.	1.2	33
203	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	2.0	33
204	Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. <i>Clinical Nutrition</i> , 2011, 30, 616-623.	2.3	32
205	Placebo effect in child and adolescent psychiatric trials. <i>European Neuropsychopharmacology</i> , 2012, 22, 787-799.	0.3	32
206	Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. <i>Lancet Psychiatry</i> , 2022, 9, 46-58.	3.7	32
207	Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2013, 150, 421-426.	1.1	31
208	Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. <i>Psychological Medicine</i> , 2020, 50, 2702-2710.	2.7	31
209	Neurological soft signs in adolescents with first episode psychosis. <i>European Psychiatry</i> , 2006, 21, 283-287.	0.1	30
210	Neurological soft signs in adolescents with first episode psychosis: Two-year followup. <i>Psychiatry Research</i> , 2008, 161, 344-348.	1.7	30
211	Specialty Care Programme for Autism Spectrum Disorders in an Urban Population: A Case-Management Model for Health Care Delivery in an asd Population. <i>European Psychiatry</i> , 2013, 28, 102-109.	0.1	30
212	Polypharmacy with antidepressants in children and adolescents. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1063-1082.	1.0	30
213	Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. <i>Molecular Autism</i> , 2019, 10, 17.	2.6	30
214	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. <i>European Neuropsychopharmacology</i> , 2020, 34, 76-86.	0.3	30
215	Mental health services during the first wave of the COVID-19 pandemic in Europe: Results from the EPA Ambassadors Survey and implications for clinical practice. <i>European Psychiatry</i> , 2021, 64, e41.	0.1	30
216	Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs. <i>Human Brain Mapping</i> , 2022, 43, 300-328.	1.9	30

#	ARTICLE	IF	CITATIONS
217	Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. <i>European Neuropsychopharmacology</i> , 2021, 48, 3-31.	0.3	30
218	Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts. <i>Psychiatric Genetics</i> , 2008, 18, 213-218.	0.6	29
219	Insular pathology in young people with high-functioning autism and first-episode psychosis. <i>Psychological Medicine</i> , 2017, 47, 2472-2482.	2.7	29
220	A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. <i>European Neuropsychopharmacology</i> , 2021, 48, 49-88.	0.3	29
221	Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. <i>Molecular Psychiatry</i> , 2022, 27, 3510-3519.	4.1	29
222	Multicenter Study of Brain Volume Abnormalities in Children and Adolescent-Onset Psychosis. <i>Schizophrenia Bulletin</i> , 2011, 37, 1270-1280.	2.3	28
223	Neurological Adverse Effects of Antipsychotics in Children and Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 686-693.	0.7	28
224	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. <i>NPJ Schizophrenia</i> , 2019, 5, 12.	2.0	28
225	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting geneâ€environment interaction. The EUGEI study. <i>Psychological Medicine</i> , 2020, 50, 1884-1897.	2.7	28
226	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. <i>Schizophrenia Research</i> , 2021, 227, 10-17.	1.1	28
227	Universal and Selective Interventions to Prevent Poor Mental Health Outcomes in Young People: Systematic Review and Meta-analysis. <i>Harvard Review of Psychiatry</i> , 2021, 29, 196-215.	0.9	28
228	Findings of proton magnetic resonance spectrometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2007, 156, 33-42.	0.9	27
229	Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2018, 48, 1592-1607.	2.7	27
230	Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model. <i>European Neuropsychopharmacology</i> , 2019, 29, 880-896.	0.3	27
231	Intracranial and subcortical volumes in adolescents with <scp>earlyâ€onset</scp> psychosis: A multisite <scp>megaâ€analysis</scp> from the <scp>ENIGMA</scp> consortium. <i>Human Brain Mapping</i> , 2022, 43, 373-384.	1.9	27
232	A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data. <i>Translational Psychiatry</i> , 2020, 10, 211.	2.4	27
233	Improving quality at the hospital psychiatric ward level through the use of the EFQM model. <i>International Journal for Quality in Health Care</i> , 2007, 19, 74-79.	0.9	26
234	The affective dimension of earlyâ€onset psychosis and its relationship with suicide. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2015, 56, 747-755.	3.1	26

#	ARTICLE	IF	CITATIONS
235	Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study. <i>European Neuropsychopharmacology</i> , 2017, 27, 350-359.	0.3	26
236	Predominance of Symptoms Over Time in Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 327-337.	1.1	26
237	Clinical effectiveness of new generation antipsychotics in adolescent patients. <i>European Neuropsychopharmacology</i> , 2004, 14, S471-S479.	0.3	25
238	Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry. <i>European Child and Adolescent Psychiatry</i> , 2011, 20, 67-70.	2.8	25
239	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. <i>EClinicalMedicine</i> , 2021, 36, 100909.	3.2	25
240	Subtly altered topological asymmetry of brain structural covariance networks in autism spectrum disorder across 43 datasets from the ENIGMA consortium. <i>Molecular Psychiatry</i> , 2022, 27, 2114-2125.	4.1	25
241	Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2008, 162, 91-100.	0.9	24
242	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2013, 6, 4-16.	0.2	24
243	Oxidative/Nitrosative Stress in Psychiatric Disorders: Are We There Yet?. <i>Schizophrenia Bulletin</i> , 2014, 40, 960-962.	2.3	24
244	La funci3n ejecutiva est3 alterada en los trastornos del espectro autista, pero esta no correlaciona con la inteligencia. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2016, 9, 39-50.	1.0	24
245	Regional specificity of thalamic volume deficits in male adolescents with early-onset psychosis. <i>British Journal of Psychiatry</i> , 2012, 200, 30-36.	1.7	23
246	Twenty-Four Months of Antipsychotic Treatment in Children and Adolescents With First Psychotic Episode. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 463-471.	0.7	23
247	Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 1149-1160.	2.8	23
248	Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2016, 9, 158-173.	0.2	23
249	Antipsic3ticos inyectables de liberaci3n prolongada para el tratamiento de la esquizofrenia en Espa�a. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2019, 12, 92-105.	1.0	23
250	Primary prevention of depression: An umbrella review of controlled interventions. <i>Journal of Affective Disorders</i> , 2021, 294, 957-970.	2.0	23
251	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	4.1	23
252	Neurological soft signs in juvenile patients with Asperger syndrome, early-onset psychosis, and healthy controls. <i>Microbial Biotechnology</i> , 2010, 4, 283-290.	0.9	22

#	ARTICLE	IF	CITATIONS
253	Dysbindinâ€1 gene contributes differentially to earlyâ€and adultâ€onset forms of functional psychosis. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 322-333.	1.1	22
254	Psychoeducational Group Intervention for Adolescents With Psychosis and Their Families: A Two-Year Follow-Up. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 984-990.	0.3	22
255	Psychotic-like experiences, polygenic risk scores for schizophrenia, and structural properties of the salience, default mode, and central-executive networks in healthy participants from UK Biobank. <i>Translational Psychiatry</i> , 2020, 10, 122.	2.4	22
256	Migration history and risk of psychosis: results from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2022, 52, 2972-2984.	2.7	22
257	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2022, 299, 393-407.	2.0	22
258	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. <i>PLoS ONE</i> , 2016, 11, e0160949.	1.1	22
259	Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2023, 62, 151-168.	0.3	22
260	Association between relative temporal and prefrontal sulcal cerebrospinal fluid and illness duration in schizophrenia. <i>Schizophrenia Research</i> , 2002, 58, 305-312.	1.1	21
261	Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study. <i>Schizophrenia Research</i> , 2008, 99, 23-28.	1.1	21
262	Role of serotonergic-related systems in suicidal behavior: Data from a caseâ€control association study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1518-1524.	2.5	21
263	Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study. <i>European Psychiatry</i> , 2012, 27, 267-274.	0.1	21
264	Assessment Tools for Soft Signs. <i>Psychiatric Annals</i> , 2003, 33, 170-176.	0.1	21
265	Effects of MDMA on blood glucose levels and brain glucose metabolism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 916-925.	3.3	20
266	Association between Heroin Dependence and 5-HT _{2A} Receptor Gene Polymorphisms. <i>European Addiction Research</i> , 2008, 14, 47-52.	1.3	20
267	Twelve-month follow-up of family communication and psychopathology in children and adolescents with a first psychotic episode (CAFEPS study). <i>Psychiatry Research</i> , 2011, 185, 72-77.	1.7	20
268	Practitioner Review: Longâ€term pharmacological treatment of pediatric bipolar disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2014, 55, 959-980.	3.1	20
269	Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimerâ€s disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 87-93.	2.9	20
270	Polymorphisms of the ILâ€1 Gene Complex Are Associated With Alcohol Dependence in Spanish Caucasians: Data From an Association Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 2147-2153.	1.4	19

#	ARTICLE	IF	CITATIONS
271	Interactions between functional serotonergic polymorphisms and demographic factors influence personality traits in healthy Spanish Caucasians. <i>Psychiatric Genetics</i> , 2010, 20, 171-178.	0.6	19
272	Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 1447-1459.	2.8	19
273	Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance. <i>Psychological Medicine</i> , 2017, 47, 193-197.	2.7	19
274	Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 38-46.	2.9	19
275	Reconceptualising treatment-resistant depression as difficult-to-treat depression. <i>Lancet Psychiatry</i> , 2021, 8, 14-15.	3.7	19
276	Predictors of Functional and Clinical Outcome in Early-Onset First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1441-e1448.	1.1	19
277	CYSTICERCOSIS IN CHRONIC PSYCHIATRIC INPATIENTS FROM A VENEZUELAN COMMUNITY. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 504-509.	0.6	19
278	Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2011, 37, 405-415.	2.3	18
279	Estimation of the Intelligence Quotient Using Wechsler Intelligence Scales in Children and Adolescents with Asperger Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2012, 42, 116-122.	1.7	18
280	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 4-20.	1.0	18
281	Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis. <i>Schizophrenia Bulletin</i> , 2019, 45, 57-68.	2.3	18
282	Aggression subtypes relate to distinct resting state functional connectivity in children and adolescents with disruptive behavior. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 1237-1249.	2.8	18
283	The effects of callous-unemotional traits and aggression subtypes on amygdala activity in response to negative faces. <i>Psychological Medicine</i> , 2022, 52, 476-484.	2.7	18
284	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. <i>European Psychiatry</i> , 2021, 64, e25.	0.1	18
285	Genetic underpinnings of sociability in the general population. <i>Neuropsychopharmacology</i> , 2021, 46, 1627-1634.	2.8	18
286	Graph Convolutional Networks Reveal Network-Level Functional Dysconnectivity in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 881-892.	2.3	18
287	Gray matter changes and cognitive predictors of 2-year follow-up abnormalities in early-onset first-episode psychosis. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 113-126.	2.8	17
288	Mobile App-Based Intervention for Adolescents With First-Episode Psychosis: Study Protocol for a Pilot Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 27.	1.3	17

#	ARTICLE	IF	CITATIONS
289	The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1674-1684.	2.3	17
290	Antipsychotic effects on auditory sensory gating in schizophrenia patients. <i>European Neuropsychopharmacology</i> , 2009, 19, 905-909.	0.3	16
291	Present and future of developmental neuropsychopharmacology. <i>European Neuropsychopharmacology</i> , 2015, 25, 703-712.	0.3	16
292	Cortical morphometry in frontoparietal and default mode networks in mathematically gifted adolescents. <i>Human Brain Mapping</i> , 2016, 37, 1893-1902.	1.9	16
293	Personality organization and its association with clinical and functional features in borderline personality disorder. <i>Psychiatry Research</i> , 2018, 262, 393-399.	1.7	16
294	Digital health technologies in clinical trials for central nervous system drugs: an EU regulatory perspective. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 83-84.	21.5	16
295	Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia. <i>Nature Communications</i> , 2022, 13, 51.	5.8	16
296	Efectos secundarios del tratamiento antipsicótico en niños y adolescentes naïve o quasi-naïve: diseño de un protocolo de seguimiento y resultados basales. <i>Revista De Psiquiatría Y Salud Mental</i> , 2012, 5, 217-228.	1.0	15
297	10Kin1day: A Bottom-Up Neuroimaging Initiative. <i>Frontiers in Neurology</i> , 2019, 10, 425.	1.1	15
298	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021, 64, e7.	0.1	15
299	Progressive Brain Changes in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 310-311.	2.3	14
300	Cognition and functionality in delusional disorder. <i>European Psychiatry</i> , 2019, 55, 52-60.	0.1	14
301	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 517-529.	2.3	14
302	Mental health care and COVID-19. <i>Lancet Psychiatry</i> , 2020, 7, 1013.	3.7	14
303	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. <i>Psychological Medicine</i> , 2022, 52, 1910-1922.	2.7	14
304	Executive functioning and emotion recognition in youth with oppositional defiant disorder and/or conduct disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 539-551.	1.3	14
305	Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 565-573.	2.9	14
306	Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries. <i>Lancet Psychiatry</i> , 2022, 9, 113-124.	3.7	14

#	ARTICLE	IF	CITATIONS
307	Posttraumatic stress disorder in victims of the March 11 attacks in Madrid admitted to a hospital emergency room: 6-month follow-up. <i>European Psychiatry</i> , 2006, 21, 143-151.	0.1	13
308	QTc Changes after 6 Months of Second-Generation Antipsychotic Treatment in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 381-383.	0.7	13
309	Development and psychometric properties of the Suicidality: Treatment Occurring in Paediatrics (STOP) Suicidality Assessment Scale (STOP-SAS) in children and adolescents. <i>BMC Pediatrics</i> , 2016, 16, 213.	0.7	13
310	Gene-environment interaction as a predictor of early adjustment in first episode psychosis. <i>Schizophrenia Research</i> , 2017, 189, 196-203.	1.1	13
311	Candidate gene associations studies in psychiatry: time to move forward. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 1-2.	1.8	13
312	Specific cortical and subcortical alterations for reactive and proactive aggression in children and adolescents with disruptive behavior. <i>NeuroImage: Clinical</i> , 2020, 27, 102344.	1.4	13
313	Dissimilarity in Sulcal Width Patterns in the Cortex can be Used to Identify Patients With Schizophrenia With Extreme Deficits in Cognitive Performance. <i>Schizophrenia Bulletin</i> , 2021, 47, 552-561.	2.3	13
314	Omega-3 fatty acids during adolescence prevent schizophrenia-related behavioural deficits: Neurophysiological evidences from the prenatal viral infection with PolyI:C. <i>European Neuropsychopharmacology</i> , 2021, 46, 14-27.	0.3	13
315	Interleukin-1 Gene Complex in Schizophrenia: An Association Study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 678-680.	1.1	12
316	A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2007, 17, 456-463.	0.3	12
317	Psychiatric comorbidities in Asperger syndrome are related with polygenic overlap and differ from other Autism subtypes. <i>Translational Psychiatry</i> , 2020, 10, 258.	2.4	12
318	A normative chart for cognitive development in a genetically selected population. <i>Neuropsychopharmacology</i> , 2022, 47, 1379-1386.	2.8	12
319	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. <i>Translational Psychiatry</i> , 2021, 11, 423.	2.4	12
320	The enduring gap in educational attainment in schizophrenia according to the past 50 years of published research: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2022, 9, 565-573.	3.7	12
321	Association study of the interleukin-1 gene complex and tumor necrosis factor alpha gene with suicide attempts. <i>Psychiatric Genetics</i> , 2008, 18, 147-150.	0.6	11
322	Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders. <i>Human Brain Mapping</i> , 2019, 40, 1643-1653.	1.9	11
323	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia " data from the OPTiMiSE trial. <i>Psychiatry Research</i> , 2020, 289, 112970.	1.7	11
324	The interplay between functioning problems and symptoms in first episode of psychosis: An approach from network analysis. <i>Journal of Psychiatric Research</i> , 2021, 136, 265-273.	1.5	11

#	ARTICLE	IF	CITATIONS
325	High Degree of Tolerability for Monotherapy With High Doses of Quetiapine. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 1048-1049.	1.1	11
326	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. <i>Biological Psychiatry</i> , 2022, 92, 299-313.	0.7	11
327	Nonverbal Delayed Recognition in the Relatives of Schizophrenia Patients With or Without Schizophrenia Spectrum. <i>Biological Psychiatry</i> , 2008, 63, 498-504.	0.7	10
328	Obstetric complications as a risk factor for first psychotic episodes in childhood and adolescence. <i>European Child and Adolescent Psychiatry</i> , 2009, 18, 180-184.	2.8	10
329	Self-Perceived Needs Are Related to Violent Behavior Among Schizophrenia Outpatients. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 666-671.	0.5	10
330	The Madrid Declaration: why we need a coordinated Europe-wide effort in mental health research. <i>British Journal of Psychiatry</i> , 2011, 198, 253-255.	1.7	10
331	Executive function is affected in autism spectrum disorder, but does not correlate with intelligence. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2016, 9, 39-50.	0.2	10
332	A developmental approach to dimensional expression of psychopathology in child and adolescent offspring of parents with bipolar disorder. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 1165-1175.	2.8	10
333	Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1081.	1.0	10
334	Distinct associations between fronto-striatal glutamate concentrations and callous-unemotional traits and proactive aggression in disruptive behavior. <i>Cortex</i> , 2019, 121, 135-146.	1.1	10
335	Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness. <i>Schizophrenia Bulletin</i> , 2020, 46, 846-856.	2.3	10
336	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. <i>Psychological Medicine</i> , 2022, 52, 1777-1783.	2.7	10
337	Functional Magnetic Resonance Imaging Connectivity Accurately Distinguishes Cases With Psychotic Disorders From Healthy Controls, Based on Cortical Features Associated With Brain Network Development. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 1125-1134.	1.1	10
338	The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2474.	1.0	10
339	Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study. <i>Psychological Medicine</i> , 0, , 1-9.	2.7	10
340	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110440.	2.5	10
341	Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110463.	2.5	10
342	Age-related brain deviations and aggression. <i>Psychological Medicine</i> , 2023, 53, 4012-4021.	2.7	10

#	ARTICLE	IF	CITATIONS
343	Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLIM): justificación, objetivos, diseño y descripción de la muestra. <i>Revista De Psiquiatría Y Salud Mental</i> , 2014, 7, 166-178.	1.0	9
344	Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder. <i>PLoS ONE</i> , 2018, 13, e0208412.	1.1	9
345	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMISE trial. <i>Schizophrenia Research</i> , 2020, 223, 271-278.	1.1	9
346	Psychiatry in the aftermath of COVID-19. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2020, 13, 105-110.	0.2	9
347	Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2022, 145, 302-308.	1.5	9
348	The effects of callous-unemotional traits and aggression subtypes on amygdala activity in response to negative faces – ERRATUM. <i>Psychological Medicine</i> , 2020, , 1-1.	2.7	9
349	Subgrouping children and adolescents with disruptive behaviors: symptom profiles and the role of callous-unemotional traits. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 51-66.	2.8	9
350	Authors' reply to "on the existence of a linguistic distance in schizophrenia". <i>Psychological Medicine</i> , 2022, 52, 798-799.	2.7	9
351	Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMISE Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 444-455.	2.3	9
352	Sex Differences in Lifespan Trajectories and Variability of Human Sulcal and Gyral Morphology. <i>Cerebral Cortex</i> , 2021, 31, 5107-5120.	1.6	9
353	Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI). <i>Schizophrenia Bulletin</i> , 2022, 48, 575-589.	2.3	9
354	Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. <i>Psychological Medicine</i> , 2023, 53, 3396-3405.	2.7	9
355	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 1104-1114.	2.3	9
356	Leukocyte telomere length in patients with schizophrenia and related disorders: a meta-analysis of case-control studies. <i>Molecular Psychiatry</i> , 2022, 27, 2968-2975.	4.1	9
357	Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs. <i>Pharmacopsychiatry</i> , 2022, 55, 233-245.	1.7	9
358	Actitud respecto a la medicación antipsicótica como factor predictivo de la suspensión del tratamiento antipsicótico en el período inicial de la psicosis de inicio temprano. <i>Revista De Psiquiatría Y Salud Mental</i> , 2008, 1, 10-17.	1.0	8
359	Investigación en salud mental en España: algo más que brotes verdes. <i>Revista De Psiquiatría Y Salud Mental</i> , 2012, 5, 211-213.	1.0	8
360	Secondary effects of antipsychotic treatment in naïve or quasi-naïve children and adolescents: Design of a follow-up protocol and baseline results. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2012, 5, 217-228.	0.2	8

#	ARTICLE	IF	CITATIONS
361	First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards). <i>Schizophrenia Bulletin</i> , 2015, 41, 1205-1206.	2.3	8
362	Atypical age-dependency of executive function and white matter microstructure in children and adolescents with autism spectrum disorders. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 1361-1376.	2.8	8
363	The complex association between the antioxidant defense system and clinical status in early psychosis. <i>PLoS ONE</i> , 2018, 13, e0194685.	1.1	8
364	Gambling Dual Disorder: A Dual Disorder and Clinical Neuroscience Perspective. <i>Frontiers in Psychiatry</i> , 2020, 11, 589155.	1.3	8
365	Demographic and Clinical Characteristics, Including Subsyndromal Symptoms Across Bipolar-Spectrum Disorders in Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 222-234.	0.7	8
366	Calling for the integration of children's mental health and protection into COVID-19 responses. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2021, 14, 113-116.	1.0	8
367	SIBUTRAMINE FOR COMPULSIVE EATING IN HYPOTHALAMIC DEFICIENCY. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2002, 41, 1147-1148.	0.3	7
368	Child and adolescent neuropsychopharmacology: Now or never. <i>European Neuropsychopharmacology</i> , 2011, 21, 563-564.	0.3	7
369	Physical comorbidity in mental illness in paediatric population: need for an integrated health care approach to paediatrics and child psychiatry. <i>European Child and Adolescent Psychiatry</i> , 2011, 20, 379-380.	2.8	7
370	Gender effects on brain changes in early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 1193-1205.	2.8	7
371	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2017, 10, 4-20.	0.2	7
372	The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies. <i>NPJ Schizophrenia</i> , 2017, 3, 40.	2.0	7
373	DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 568982.	1.3	7
374	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. <i>Psychological Medicine</i> , 2021, 51, 2074-2082.	2.7	7
375	Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study. <i>Psychological Medicine</i> , 2022, 52, 3668-3676.	2.7	7
376	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1. <i>Frontiers in Psychiatry</i> , 2021, 12, 701729.	1.3	7
377	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. <i>European Neuropsychopharmacology</i> , 2022, 59, 45-55.	0.3	7
378	Lack of association between endothelial nitric oxide synthase (NOS3) gene polymorphisms and suicide attempts. <i>Behavioral and Brain Functions</i> , 2007, 3, 32.	1.4	6

#	ARTICLE	IF	CITATIONS
379	Structural magnetic resonance imaging data do not help support DSM-5 autism spectrum disorder category. <i>Research in Autism Spectrum Disorders</i> , 2013, 7, 333-343.	0.8	6
380	Desarrollo profesional en investigaci3n traslacional en neurociencias y salud mental: educaci3n y formaci3n dentro del Centro de Investigaci3n Biom3dica en Red en Salud Mental. <i>Revista De Psiquiatr3a Y Salud Mental</i> , 2015, 8, 65-74.	1.0	6
381	Going Beyond "trial-and-error" in Psychiatric Treatments: OPTiMiSE-ing the Treatment of First Episode of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 546-548.	2.3	6
382	Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 449-457.	0.7	6
383	One-Year Prospective Study of Liver Function Tests in Children and Adolescents on Second-Generation Antipsychotics: Is There a Link with Metabolic Syndrome?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 463-473.	0.7	6
384	A longitudinal comparison of two neurocognitive test batteries in patients with schizophrenia and healthy volunteers: Time effects on neuropsychological performance and their relation to functional outcome. <i>Schizophrenia Research</i> , 2020, 216, 347-356.	1.1	6
385	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. <i>Schizophrenia Research</i> , 2020, 230, 104-107.	1.1	6
386	The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens. <i>Schizophrenia Research</i> , 2021, 228, 462-471.	1.1	6
387	Efficacy of a Web-Enabled, School-Based, Preventative Intervention to Reduce Bullying and Improve Mental Health in Children and Adolescents: Study Protocol for a Cluster Randomized Controlled Trial. <i>Frontiers in Pediatrics</i> , 2021, 9, 628984.	0.9	6
388	Calling for the integration of children's mental health and protection into COVID-19 responses. <i>Revista De Psiquiatr3a Y Salud Mental (English Edition)</i> , 2021, 14, 113-116.	0.2	6
389	PIENSA: Development of an Early Intervention Program for Adolescents With Early-Onset Psychosis and Their Families. <i>Adolescent Psychiatry (Hilversum, Netherlands)</i> , 2012, 2, 229-236.	0.1	6
390	A polygenic approach to the association between smoking and schizophrenia. <i>Addiction Biology</i> , 2022, 27, e13104.	1.4	6
391	Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study. <i>Psychological Medicine</i> , 2023, 53, 3471-3479.	2.7	6
392	Attitude Toward Antipsychotic Medication as a Predictor of Antipsychotic Treatment Discontinuation in First-Episode Early-Onset Psychosis. <i>Revista De Psiquiatr3a Y Salud Mental (English Edition)</i> , 2008, 1, 10-17.	0.2	5
393	The state of psychiatry in Spain. <i>International Review of Psychiatry</i> , 2012, 24, 347-355.	1.4	5
394	Antioxidant defense system and family environment in adolescents with family history of psychosis. <i>BMC Psychiatry</i> , 2012, 12, 200.	1.1	5
395	Prevalence of premorbid personality disorder and its clinical correlates in patients with delusional disorder. <i>Psychiatry Research</i> , 2013, 210, 986-993.	1.7	5
396	Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description. <i>Revista De Psiquiatr3a Y Salud Mental (English Edition)</i> , 2014, 7, 166-178.	0.2	5

#	ARTICLE	IF	CITATIONS
397	Un tratamiento integral para el trastorno por déficit de atención e hiperactividad en toda Europa. Revista De Psiquiatría Y Salud Mental, 2015, 8, 197-198.	1.0	5
398	Moving interventions from after to before diagnosis. World Psychiatry, 2017, 16, 275-276.	4.8	5
399	One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. Revista De Psiquiatría Y Salud Mental (English Edition), 2019, 12, 135-140.	0.2	5
400	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. Frontiers in Psychiatry, 2019, 10, 676.	1.3	5
401	CIBERSAM: Ten years of collaborative translational research in mental disorders. Revista De Psiquiatría Y Salud Mental (English Edition), 2019, 12, 1-8.	0.2	5
402	Development and psychometric properties of the "Suicidality: Treatment Occurring in Paediatrics (STOP) Risk and Resilience Factors Scales" in adolescents. European Child and Adolescent Psychiatry, 2020, 29, 153-165.	2.8	5
403	Needs of people with psychosis and their caregivers: "In their own voice". Revista De Psiquiatría Y Salud Mental (English Edition), 2020, 13, 80-89.	0.2	5
404	Exploring the biological role of postzygotic and germinal de novo mutations in ASD. Scientific Reports, 2021, 11, 319.	1.6	5
405	Necesidades de las personas con psicosis y sus cuidadores: "en voz propia". Revista De Psiquiatría Y Salud Mental, 2020, 13, 80-89.	1.0	5
406	Violence in schizophrenia. Dialogues in Clinical Neuroscience, 2000, 2, 392-393.	1.8	5
407	P.3.a.025 Open-label randomized trial comparing the efficacy and tolerability of quetiapine and olanzapine in first episode psychosis in adolescents. European Neuropsychopharmacology, 2006, 16, S377-S378.	0.3	4
408	Someone is not listening to the facts: there is little psychiatry outside child and adolescent psychiatry. European Child and Adolescent Psychiatry, 2012, 21, 475-476.	2.8	4
409	To treat or not to treat? and How to treat? Two questions whose answers are far removed from evidence informed practice in child psychiatry. European Child and Adolescent Psychiatry, 2013, 22, 521-522.	2.8	4
410	The need for paediatric registries to assess long-term brain effects of psychotropic medications: The case of bipolar disorder. European Neuropsychopharmacology, 2018, 28, 1181-1184.	0.3	4
411	Development of an early intervention programme for adolescents with emotion dysregulation and their families: Actions for the treatment of adolescent personality (ATraPA). Microbial Biotechnology, 2020, 14, 619-624.	0.9	4
412	Reward and Punishment Sensitivity are Associated with Cross-disorder Traits. Psychiatry Research, 2021, 298, 113795.	1.7	4
413	The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMISE study. Schizophrenia Research, 2021, 231, 100-107.	1.1	4
414	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. Schizophrenia Bulletin, 2021, 47, 1653-1662.	2.3	4

#	ARTICLE	IF	CITATIONS
415	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. <i>Brain Sciences</i> , 2021, 11, 908.	1.1	4
416	Fronto-Parietal Gray Matter Volume Loss Is Associated with Decreased Working Memory Performance in Adolescents with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3929.	1.0	4
417	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. <i>Schizophrenia Research</i> , 2021, 236, 69-79.	1.1	4
418	Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 21-35.	2.2	4
419	Should psychiatry deal only with mental disorders without an identified medical aetiology?. <i>World Psychiatry</i> , 2016, 15, 22-23.	4.8	3
420	When the healthcare does not follow the evidence: The case of the lack of early intervention programs for psychosis in Spain. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017, 10, 78-86.	0.2	3
421	Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2019, 12, 92-105.	0.2	3
422	Affective symptom dimensions in early-onset psychosis over time: a principal component factor analysis of the Young Mania Rating Scale and the Hamilton Depression Rating Scale. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 1715-1728.	2.8	3
423	How does neighbourhood socio-economic status affect the interrelationships between functioning dimensions in first episode of psychosis? A network analysis approach. <i>Health and Place</i> , 2021, 69, 102555.	1.5	3
424	Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty. <i>European Neuropsychopharmacology</i> , 2021, 52, 72-83.	0.3	3
425	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. <i>Revista De Psiquiatría Y Salud Mental</i> , 2021, , .	1.0	3
426	Cortical thinning over two years after first-episode psychosis depends on age of onset. <i>NPJ Schizophrenia</i> , 2022, 8, 20.	2.0	3
427	Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and Alzheimer's disease patients. <i>PLoS ONE</i> , 2022, 17, e0263769.	1.1	3
428	P.3.a.032 Cognitive efficacy of quetiapine and olanzapine in early onset first episode psychosis. <i>European Neuropsychopharmacology</i> , 2006, 16, S381-S382.	0.3	2
429	Longitudinal course of cognition in schizophrenia. <i>British Journal of Psychiatry</i> , 2009, 195, 84-84.	1.7	2
430	Clinical subtyping and early detection: short-term challenges for child and adolescent psychiatry. <i>European Child and Adolescent Psychiatry</i> , 2010, 19, 627-628.	2.8	2
431	Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza. <i>Psiquiatría Biológica</i> , 2011, 18, 55-67.	0.0	2
432	P.7.a.009 Predictors of diagnosis of nonaffective acute remitting psychosis in patients with early-onset first episodes of psychosis. <i>European Neuropsychopharmacology</i> , 2012, 22, S418-S419.	0.3	2

#	ARTICLE	IF	CITATIONS
433	Mental Health Research in Spain: A bit more than green shoots. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2012, 5, 211-213.	0.2	2
434	Development of the Spanish Brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2014, 7, 113-120.	0.2	2
435	More Treatment for Those Most in Need? A Foregone Conclusion?. <i>Schizophrenia Bulletin</i> , 2015, 41, 26-27.	2.3	2
436	31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S50-S51.	2.3	2
437	Psychiatrists are experts when it comes to missing boats. Will prevention be the next one?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 869-870.	1.8	2
438	Role of Executive Function in Response to a Problem Solving Based Psychoeducational Intervention in Adolescents with Psychosis: The PIENSA Trial Revisited. <i>Journal of Clinical Medicine</i> , 2019, 8, 2108.	1.0	2
439	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. <i>Schizophrenia Bulletin Open</i> , 0, .	0.9	2
440	Building up resilience in an uncertain world: mental health challenges in the aftermath of the first modern pandemic. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1001-1003.	1.8	2
441	La humanizaci3n en los planes de salud mental en Espa�a. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2021, , .	1.0	2
442	Risk factors for respiratory disease in chronic psychiatric in patients. <i>European Journal of Psychiatry</i> , 2007, 21, .	0.7	2
443	Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism. <i>Journal of Autism and Developmental Disorders</i> , 2023, 53, 66-79.	1.7	2
444	Evaluation of the continuation of care between psychiatric hospitalization units and the outpatient clinics in the community. <i>Actas Espanolas De Psiquiatria</i> , 2005, 33, 273-9.	0.1	2
445	Subjective response to neuroleptics in schizophrenia. <i>Schizophrenia Research</i> , 1997, 24, 263-264.	1.1	1
446	Fluoxetine as an add-on medication to typical antipsychotics in chronic schizophrenia. <i>Schizophrenia Research</i> , 2000, 41, 211.	1.1	1
447	Management of acutely ill patients in the hospital setting: focus on quetiapine. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 61-72.	1.2	1
448	The genetic contribution to first psychotic episodes in children and adolescents of the child and adolescent first-episode psychosis study. <i>Psychiatric Genetics</i> , 2008, 18, 151-152.	0.6	1
449	FRONTAL CORTICAL THICKNESS IS ASSOCIATED WITH CLINICAL IMPROVEMENT OF NEGATIVE SYMPTOMS IN MALE ADOLESCENTS WITH EARLY-ONSET FIRST-EPISODE PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 225-226.	1.1	1
450	Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2010, 3, 152-167.	0.2	1

#	ARTICLE	IF	CITATIONS
451	The bipolar â€œdepressive continuum in the National Epidemiologic Survey on Alcohol and Related Conditions. <i>Bipolar Disorders</i> , 2013, 15, 112-113.	1.1	1
452	Child neuropsychopharmacology: good newsâ€¦ the glass is half full. <i>World Psychiatry</i> , 2013, 12, 128-129.	4.8	1
453	Assessment for subtle neurological signs. , 0, , 333-343.		1
454	Building up careers in translational neuroscience and mental health research: Education and training in the Centre for Biomedical Research in Mental Health. <i>Revista De PsiquiatrÃa Y Salud Mental (English)</i> Tj ETQq0 00zrgBT /Overlock 10	0.2	0
455	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Focus (American)</i> Tj ETQq1 1 0.784314 rgBT /Overlo	0.78	1
456	Safety of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study. <i>European Neuropsychopharmacology</i> , 2017, 27, S1099.	0.3	1
457	Effectiveness of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study. <i>European Neuropsychopharmacology</i> , 2017, 27, S1100-S1101.	0.3	1
458	Science and fashion: inflammation and oxidative stress in psychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 105-106.	1.8	1
459	109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis. <i>CNS Spectrums</i> , 2018, 23, 70-71.	0.7	1
460	Reply to: Another Vision From the Coronavirus Health Crisis in Spain: The Perspective From the Plena inclusiÃ³n Developmental Disabilities Associative Movement. <i>Biological Psychiatry</i> , 2021, 89, e19-e20.	0.7	1
461	Understanding the Influence of Personality Traits on Risk of Suicidal Behaviour in Schizophrenia Spectrum Disorders: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4604.	1.0	1
462	Longitudinal Allometry of Sulcal Morphology in Health and Schizophrenia. <i>Journal of Neuroscience</i> , 2022, 42, 3704-3715.	1.7	1
463	Prediction of violence in schizophrenic inpatients. <i>Schizophrenia Research</i> , 1997, 24, 247.	1.1	0
464	S17.02 Structural findings in neuropsychiatric disorders: The role of stress. <i>European Psychiatry</i> , 2000, 15, 246s-246s.	0.1	0
465	P.3.c.050 Psychopathology and metabolic syndrome (MS) in psychotic patients: the CLAMORS study. <i>European Neuropsychopharmacology</i> , 2006, 16, S423-S424.	0.3	0
466	Genes and impulsivity: comment to the study of Nomura et al. on â€œInvolvement of a polymorphism in the 5-HT2A receptor gene in impulsive behavior. <i>Psychopharmacology</i> 187:30-35. <i>Psychopharmacology</i> , 2006, 188, 128-129.	1.5	0
467	P.3.02 Metabolic side effects with second generation antipsychotics in antipsychotic-naïve adolescents. <i>European Neuropsychopharmacology</i> , 2007, 17, S71.	0.3	0
468	S.18.04 Early-onset psychotic patients growing up: clinical, imaging and neuropsychological findings. <i>European Neuropsychopharmacology</i> , 2008, 18, S182-S183.	0.3	0

#	ARTICLE	IF	CITATIONS
469	A simulation model to estimate the coronary heart disease risk in schizophrenic patients treated with second-generation-antipsychotic drugs: A Spanish perspective. <i>European Psychiatry</i> , 2008, 23, S139.	0.1	0
470	S.01.03 Treatment of bipolar disorders in children and adolescents. <i>European Neuropsychopharmacology</i> , 2009, 19, S176.	0.3	0
471	S.21.02 Efficacy and safety of antipsychotics in early onset psychosis. <i>European Neuropsychopharmacology</i> , 2009, 19, S207.	0.3	0
472	Prevalence of Metabolic Syndrome and Coronary Heart Disease Risk in Patients with Schizoaffective Disorder: Clamors Study. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
473	GENETIC VARIABILITY IN DYSBINDIN-1 GENE (DTNBP1) CONTRIBUTES DIFFERENTIALLY TO EARLY AND ADULT ONSET FUNCTIONAL PSYCHOSES AND IT IS ASSOCIATED WITH THE FAMILIAL TRANSMISSION OF IQ AND PREFRONTAL COGNITIVE DEFICITS. <i>Schizophrenia Research</i> , 2010, 117, 220-221.	1.1	0
474	FRONTAL CORTICAL THICKNESS IS ASSOCIATED WITH CLINICAL IMPROVEMENT OF NEGATIVE SYMPTOMS IN MALE ADOLESCENTS WITH EARLY-ONSET FIRST-EPISEDE PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 227-228.	1.1	0
475	P.7.a.012 Dyskinesia in naïve children and adolescents treated with olanzapine, risperidone and quetiapine: three months follow up. <i>European Neuropsychopharmacology</i> , 2010, 20, S617.	0.3	0
476	Neurobiological substrates in deficit and non deficit schizophrenia. <i>European Psychiatry</i> , 2011, 26, 2069-2069.	0.1	0
477	P.3.004 Risk for adverse health outcome in antipsychotic-naïve adolescents after 12 months of treatment with second-generation antipsychotics. <i>European Neuropsychopharmacology</i> , 2011, 21, S61-S62.	0.3	0
478	P.1.e.036 White matter microstructure in Asperger syndrome patients compared with healthy controls. <i>European Neuropsychopharmacology</i> , 2011, 21, S324.	0.3	0
479	P.1.e.038 Differences in corpus callosum composition between Asperger syndrome and healthy adolescents: a tractography study. <i>European Neuropsychopharmacology</i> , 2011, 21, S325-S326.	0.3	0
480	P.3.c.049 Risk of adverse health outcome and metabolic syndrome in adolescents treated with antipsychotics: preliminary results. <i>European Neuropsychopharmacology</i> , 2011, 21, S496-S497.	0.3	0
481	P.7.e.001 Oxidative stress and brain volume in early onset psychosis: role of glutathione levels in progressive loss of cortical grey matter. <i>European Neuropsychopharmacology</i> , 2011, 21, S608.	0.3	0
482	Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia. <i>Evidence-Based Mental Health</i> , 2011, 14, 112-112.	2.2	0
483	Psychometric properties of the Spanish version of the Diagnostic Interview for Depressive Personality. <i>European Psychiatry</i> , 2012, 27, 582-590.	0.1	0
484	The Other Side of Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2014, 171, 1145-1147.	4.0	0
485	P.7.d.011 Association between duration of untreated psychosis and functionality within family environment in early-onset first episode psychosis. <i>European Neuropsychopharmacology</i> , 2014, 24, S726.	0.3	0
486	Needs of People with Schizophrenia/Psychosis and their Caregivers: A Large Scale Survey. <i>European Psychiatry</i> , 2017, 41, S97-S97.	0.1	0

#	ARTICLE	IF	CITATIONS
487	F19. TELOMERE SHORTENING IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTH FOLLOW-UP STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S226-S226.	2.3	0
488	31. OPTIMISE-ING THE TREATMENT OF FIRST-EPISODE SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S49-S49.	2.3	0
489	F133. A LONGITUDINAL COMPARISON OF TWO NEUROCOGNITIVE ASSESSMENT PACKAGES IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY VOLUNTEERS: TIME EFFECTS ON NEUROPSYCHOLOGICAL PERFORMANCE AND ITS RELATION TO FUNCTIONAL OUTCOME. <i>Schizophrenia Bulletin</i> , 2019, 45, S304-S305.	2.3	0
490	17.2 NEGATIVE SYMPTOMS IN THE OPTIMISE COHORT: PREDICTION OF SHORT-TERM REMISSION STATE AND ASSOCIATION WITH PSYCHOSOCIAL FUNCTIONING. <i>Schizophrenia Bulletin</i> , 2019, 45, S116-S116.	2.3	0
491	17. THE OPTIMISE STUDY: AMISULPRIDE AND OLANZAPINE FOLLOWED BY OPEN-LABEL TREATMENT WITH CLOZAPINE IN FIRST-EPISODE SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2019, 45, S115-S115.	2.3	0
492	O3.1. ASSOCIATION OF EXTENT OF CANNABIS USE AND ACUTE INTOXICATION EXPERIENCES IN A MULTI-NATIONAL SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS AND CONTROLS. <i>Schizophrenia Bulletin</i> , 2019, 45, S165-S166.	2.3	0
493	Age at first episode modulates progressive cortical thinning in individuals with psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, S103-S104.	0.3	0
494	T25. THE RELATIONSHIP BETWEEN AGE AT FIRST-EPISODE AND LONGITUDINAL CORTICAL CHANGES IN FIRST-EPISODE PSYCHOSIS: A TWO-YEAR LONGITUDINAL STUDY IN AN ADOLESCENT AND ADULT-ONSET COHORT. <i>Schizophrenia Bulletin</i> , 2020, 46, S240-S241.	2.3	0
495	S80. CHILDHOOD TRAUMA AND SOCIAL COGNITION IN DELUSIONAL PSYCHOSES. <i>Schizophrenia Bulletin</i> , 2020, 46, S64-S65.	2.3	0
496	S95. DIFFERENCES IN LIFETIME PATTERNS OF PSYCHOSTIMULANTS AND THEIR IMPACT ON THE PROPORTION OF PATIENTS WITH FIRST-EPISODE PSYCHOSIS ATTRIBUTABLE TO PSYCHOSTIMULANTS USE ACROSS EUROPE. <i>Schizophrenia Bulletin</i> , 2020, 46, S70-S71.	2.3	0
497	P.389 Social withdrawal levels influence cerebellar activity during consumption of monetary rewards â€” fMRI results from the PRISM clinical study. <i>European Neuropsychopharmacology</i> , 2020, 40, S222-S223.	0.3	0
498	T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISODE SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S275-S275.	2.3	0
499	T24. CHANGES IN TELOMERE LENGTH IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTHS FOLLOW-UP STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S240-S240.	2.3	0
500	Quality of care in psychiatry is related to research activity. <i>European Psychiatry</i> , 2021, 64, e53.	0.1	0
501	Drug development in ASD, an ISCTM-ECNP joint adventure. <i>European Neuropsychopharmacology</i> , 2021, 48, 1-2.	0.3	0
502	Methodologic and Reporting Issues in Published Meta-analysisâ€”Reply. <i>JAMA Pediatrics</i> , 2021, 175, 644.	3.3	0
503	Trends in utilisation of hypnotics among Scandinavian young people. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 97-99.	2.2	0
504	Evaluating the tendencies of community practitioners who actively practice in child and adolescent psychiatry to diagnose and treat DSM-5 attenuated psychotic syndrome. <i>European Child and Adolescent Psychiatry</i> , 2021, , 1.	2.8	0

#	ARTICLE	IF	CITATIONS
505	Calidad de vida y discapacidad en pacientes con trastorno obsesivo-compulsivo. European Psychiatry (Ed Española), 2001, 8, 436-442.	0.0	0
506	El síndrome deficitario en la esquizofrenia: implicaciones para el tratamiento de los síntomas negativos. European Psychiatry (Ed Española), 2004, 11, 219-224.	0.0	0
507	S107. RANDOMIZED CONTROL TRIAL OF A MOBILE APP-BASED INTERVENTION FOR ADOLESCENTS WITH FIRST-EPIISODE PSYCHOSIS: THE THINK APP. Schizophrenia Bulletin, 2020, 46, S75-S75.	2.3	0
508	Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis. , 2020, , 303-316.		0
509	Social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. European Psychiatry, 2021, 64, S163-S163.	0.1	0
510	Prediction of drop-out and functional impairment in recent-onset schizophrenia spectrum disorders. European Psychiatry, 2021, 64, S35-S36.	0.1	0
511	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. Revista De Psiquiatría Y Salud Mental (English) Tj ETQq1 1 0.784314 rgBT /Over	0.784314	0